Why Are Steroids Mainly Used for Active Thyroid Eye Disease?
At a Glance
Steroids mainly help active thyroid eye disease because they suppress ongoing inflammation. Once the disease is inactive, bulging eyes and double vision usually come from lasting changes in fat, eye muscles, or scar tissue, which medicine cannot easily reverse.
In this answer
4 sections
When your doctor says steroids won’t work for you right now, it is usually because your Thyroid Eye Disease (TED) has moved into its inactive phase. Steroids and other immunosuppressants work best when they are targeting active inflammation [1]. If you are in the inactive phase, the active immune attack has mostly subsided. The severe symptoms you may still experience—such as bulging eyes or double vision—are primarily caused by established physical changes in the tissue, such as expanded fat, enlarged muscles, and rigid scar tissue [2]. Because medications cannot easily reverse these structural changes, your doctor will likely recommend conservative management or rehabilitative surgery instead [3].
🚨 URGENT WARNING: When Not to Wait
Elective surgery is typically delayed until the disease is inactive, but there is a crucial exception: vision-threatening disease. If you experience sudden blurred or decreased vision, loss of color vision, a new blind spot, severe eye pain, or an inability to close your eyelids, seek emergency ophthalmic care immediately. Urgent treatment—including high-dose steroids or emergency surgery—may be required to save your sight, regardless of what phase the disease is in [4][3].
Active vs. Inactive Thyroid Eye Disease
Thyroid Eye Disease generally follows a curve: it flares up, fluctuates, and often stabilizes after a period of time, commonly 18 to 24 months [5]. However, timelines vary, and the disease can reactivate.
- The Active Phase: The immune system actively attacks the tissues behind the eyes, flooding the area with inflammatory cells and fluids (edema) [6]. You may have redness, pain, and swelling. During this phase, intravenous (IV) steroids can effectively calm the inflammation [1].
- The Inactive Phase: The active inflammation subsides, but the tissues do not simply return to normal. The eye muscles and orbital fat undergo permanent remodeling, which includes fat expansion and the formation of tough, rigid scar tissue (fibrosis) [2].
Even when the active phase ends, you may still have severe symptoms. The expanded tissue and fibrosis can physically push the eye forward (proptosis) or restrict muscle movement, causing double vision (diplopia) [7][8].
Activity vs. Severity (and the CAS)
It can be incredibly frustrating to hear your disease is “inactive” when your symptoms are still severe. This is because doctors distinguish between activity and severity:
- Activity measures how much active inflammation is present (the “fire”).
- Severity measures how much the disease impacts your function and appearance (the resulting “damage”).
To measure activity, doctors use the Clinical Activity Score (CAS), grading signs like pain, redness, and swelling [9]. A CAS of 3 or higher often indicates active disease, while a lower score suggests it is inactive [10]. However, CAS is just one tool; doctors also evaluate your vision, eye movement, and corneal health, because a low CAS does not guarantee your eyes are safe or that the disease isn’t progressing [11].
Why Steroids Have Limits
Steroids work by suppressing the immune system’s release of inflammatory chemicals [6]. However, once the tissue has remodeled and formed scar tissue, the inflammation is mostly gone [12]. Steroids cannot dissolve scar tissue or shrink remodeled fat cells.
Furthermore, IV steroids carry significant risks, including elevated blood sugar, increased blood pressure, mood changes, liver strain, and higher infection risk [1]. Giving steroids to a patient with a low CAS exposes them to these heavy side effects without providing meaningful benefit to their underlying structural symptoms.
Managing the Inactive Phase
Being in the inactive phase does not mean you are out of options. Depending on your symptoms, your care team may recommend:
Conservative Management
Not everyone needs or wants surgery. You can manage residual symptoms with:
- Lubrication: Preservative-free artificial tears and nighttime ointments to protect the surface of the eye.
- Prisms: Special glasses lenses that help correct double vision.
- Lifestyle: Quitting smoking (which drastically worsens TED) and keeping your thyroid hormone levels optimized.
Rehabilitative Surgery
If you have persistent, functionally significant structural changes, elective surgery can help [4]. Doctors usually require your eye measurements and CAS to be completely stable for at least 6 months before operating [4]. Operating too early, while the tissues are still changing, can alter the surgical results.
When surgery is chosen, it is typically performed in a specific, individualized sequence [4]:
- Orbital Decompression: Removing bone or fat to create more space behind the eye, allowing it to settle back into a normal position.
- Strabismus Surgery: Adjusting the scarred eye muscles to restore alignment and fix double vision.
- Eyelid Surgery: Adjusting retracted (pulled back) eyelids so the eyes can close fully and comfortably.
Every surgery carries risks, such as worsening double vision after decompression, so these decisions must be made carefully with your orbital specialist.
Common questions in this guide
Why do steroids work better when thyroid eye disease is active?
Can inactive thyroid eye disease still cause serious symptoms?
When should I seek emergency help for thyroid eye disease?
What does the Clinical Activity Score mean in thyroid eye disease?
What can help if steroids are not recommended for inactive TED?
How long should thyroid eye disease be stable before elective surgery?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Related questions
Show more
Get notified when new evidence is published on thyrotoxic exophthalmos.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my current Clinical Activity Score (CAS), and how does it compare to my overall disease severity?
- 2.Are there any objective signs of optic nerve compression or corneal damage that we need to address immediately?
- 3.Given my specific symptoms, what are the risks, benefits, and alternatives to waiting for rehabilitative surgery?
- 4.If I choose surgery, what sequence of procedures (such as decompression, then muscle surgery) would you recommend for my anatomy?
- 5.How many months of stable measurements do you require before proceeding with elective surgery?
References
References (12)
- 1
Pharmacologic Therapies for Active Moderate-to-Severe TED: A Comprehensive Systematic Review.
Builes-Montaño CE, Román-González A, Arenas-Quintero HM, et al.
Clinical medicine insights. Endocrinology and diabetes 2026; (19()):11795514261426446 doi:10.1177/11795514261426446.
PMID: 41783234 - 2
Teprotumumab for the treatment of thyroid eye disease.
Fallahi P, Ragusa F, Paparo SR, et al.
Expert opinion on biological therapy 2023; (23(2)):123-131 doi:10.1080/14712598.2023.2172328.
PMID: 36695097 - 3
Future Projections in Thyroid Eye Disease.
Barbesino G, Salvi M, Freitag SK
The Journal of clinical endocrinology and metabolism 2022; (107(Suppl_1)):S47-S56 doi:10.1210/clinem/dgac252.
PMID: 36346684 - 4
Medical and surgical treatment of thyroid eye disease.
Hall AJH, Topliss DJ
Internal medicine journal 2022; (52(1)):14-20 doi:10.1111/imj.15067.
PMID: 32975863 - 5
Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors.
Bartalena L, Gallo D, Tanda ML, Kahaly GJ
Ophthalmic plastic and reconstructive surgery 2023; (39(6S)):S2-S8 doi:10.1097/IOP.0000000000002467.
PMID: 38054980 - 6
Orbital Clinicopathological Differences in Thyroid Eye Disease: An Analysis of Cytokines With Histopathological and Clinical Correlation.
Li Y, Tang J, Jing G, et al.
Investigative ophthalmology & visual science 2025; (66(3)):33 doi:10.1167/iovs.66.3.33.
PMID: 40100205 - 7
Longitudinal association of thyroid-stimulating immunoglobulin levels with clinical characteristics in thyroid eye disease.
Ko J, Kook KH, Yoon JS, et al.
BMJ open 2022; (12(6)):e050337 doi:10.1136/bmjopen-2021-050337.
PMID: 35728893 - 8
Quantifying Orbital Segmentation in Thyroid Eye Disease- Fat to Muscle Ratio Correlates With Restrictive Strabismus.
Armarnik S, Hilewitz D, Kinori M, et al.
American journal of ophthalmology 2026; (287()):93-100 doi:10.1016/j.ajo.2026.03.018.
PMID: 41865860 - 9
Inter-observer Variability of Clinical Activity Score: Assessments in Patients With Thyroid Eye Disease.
Perros P, Žarković M, Pearce SH, et al.
American journal of ophthalmology 2023; (252()):94-100 doi:10.1016/j.ajo.2023.03.027.
PMID: 37028695 - 10
The "Quiet TED"-A Special Subgroup of Thyroid Eye Disease.
Iñiguez-Ariza NM, Sharma A, Garrity JA, Stan MN
Ophthalmic plastic and reconstructive surgery 2021; (37(6)):551-555 doi:10.1097/IOP.0000000000001942.
PMID: 33782324 - 11
Low clinical activity score, 'progressive' thyroid eye disease: presentations of 1439 patients from a tertiary centre in Hong Kong.
Lai KKH, Aljufairi FMAA, Sebastian JU, et al.
The British journal of ophthalmology 2025; (109(6)):715-720 doi:10.1136/bjo-2024-325346.
PMID: 39798945 - 12
Thyroid eye disease: From pathogenesis to targeted therapies.
Yoon JS, Kikkawa DO
Taiwan journal of ophthalmology 2022; (12(1)):3-11 doi:10.4103/tjo.tjo_51_21.
PMID: 35399971
This explanation is for informational purposes only and does not constitute medical advice. Your ophthalmologist or orbital specialist should assess your thyroid eye disease activity, vision, and treatment options.